GxP is not one regulation — it is a family Teams from technology backgrounds entering pharmaceutical environments encounter “GxP” and treat it as a single compliance requirement. It is not. GxP is a collective term for Good Practice regulations — a family that includes GMP (Good Manufacturing Practice), GLP (Good Laboratory Practice), GCP (Good Clinical Practice), GDP (Good Distribution Practice), and others. Each applies to a different phase of the product lifecycle, and each imposes different requirements on software and AI systems operating within its scope. An AI system used in manufacturing quality control (GMP) faces different validation requirements than an AI system used in clinical trial data analysis (GCP) or laboratory test interpretation (GLP). Treating them as identical over-scopes the lighter cases and under-scopes the heavier ones. The GxP family and what each means for AI Regulation Full name Applies to AI/ML implication GMP Good Manufacturing Practice Manufacturing, QC, packaging, release testing AI in QC decisions requires full validation; changes need formal change control GLP Good Laboratory Practice Non-clinical laboratory studies, safety testing AI interpreting lab results must maintain data integrity and audit trail GCP Good Clinical Practice Clinical trials, patient data, trial conduct AI processing patient data needs privacy controls + data integrity validation GDP Good Distribution Practice Storage, transport, distribution AI in cold-chain monitoring needs calibration traceability and alert validation GVP Good Pharmacovigilance Practice Post-market safety surveillance AI in adverse event detection needs sensitivity validation (false negatives are critical) Risk-based validation: not all software requires the same depth Software in GxP environments must be validated proportional to its impact on product quality. This principle — codified in GAMP 5 and reinforced by the FDA’s Computer Software Assurance guidance — means: Category 1 (infrastructure software): Operating systems, databases — validated by the vendor, minimal user validation required. Category 3 (non-configured): Off-the-shelf software used as-is — vendor validation plus user acceptance testing. Category 4 (configured): Software configured for a specific use — configuration validation plus functional testing. Category 5 (custom): Custom-developed software including most AI/ML models — full lifecycle validation: requirements, design, coding, testing, deployment, maintenance. Most AI/ML systems in pharma land in Category 4 or 5, requiring substantial validation effort. But “substantial” does not mean “identical for all systems.” A predictive maintenance model that alerts a human who makes the decision needs less rigorous validation than a model that autonomously releases or rejects product batches. What validation actually looks like for AI systems For teams entering pharma from technology backgrounds, “validation” has a specific meaning that differs from software testing: User Requirements Specification (URS) — what the system must do in operational terms. Functional Specification (FS) — how the system achieves those requirements. Design Specification (DS) — the technical implementation. Installation Qualification (IQ) — confirmation the system is installed correctly. Operational Qualification (OQ) — confirmation it operates within defined parameters. Performance Qualification (PQ) — confirmation it performs as intended in production conditions. For AI/ML systems, PQ is the awkward one: model performance drifts as input distributions shift, so a single PQ snapshot does not stay valid forever. Our deeper treatment of GxP compliance requirements for pharma covers how to hold this lifecycle validation together for adaptive systems. The practical consequence for AI teams Engineering teams accustomed to deploying models weekly and iterating on A/B results find pharma’s change-control requirements constraining. Every model update requires documented justification, impact assessment, and re-validation proportional to the change’s risk. This is not bureaucracy for its own sake — a model error in manufacturing QC can affect patient safety. The accommodation is to design AI systems for pharma with change control in mind from the start: modular architectures where individual components can be re-validated independently, documented performance boundaries that trigger re-validation when breached, and explicit data-drift monitoring that supplies objective evidence for when re-validation is actually needed.
